Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity.
Cendrowicz E, Jacob L, Greenwald S, Tamir A, Pecker I, Tabakman R, Ghantous L, Tamir L, Kahn R, Avichzer J, Aronin A, Amsili S, Zorde-Khvalevsky E, Gozlan Y, Vlaming M, Huls G, van Meerten T, Dranitzki ME, Foley-Comer A, Pereg Y, Peled A, Chajut A, Bremer E. Cendrowicz E, et al. Among authors: huls g. J Exp Clin Cancer Res. 2022 Mar 14;41(1):97. doi: 10.1186/s13046-022-02256-x. J Exp Clin Cancer Res. 2022. PMID: 35287686 Free PMC article.
CD20-selective inhibition of CD47-SIRPα "don't eat me" signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab.
van Bommel PE, He Y, Schepel I, Hendriks MAJM, Wiersma VR, van Ginkel RJ, van Meerten T, Ammatuna E, Huls G, Samplonius DF, Helfrich W, Bremer E. van Bommel PE, et al. Among authors: huls g. Oncoimmunology. 2017 Oct 31;7(2):e1386361. doi: 10.1080/2162402X.2017.1386361. eCollection 2018. Oncoimmunology. 2017. PMID: 29308308 Free PMC article.
Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach.
de Jong MRW, Visser L, Huls G, Diepstra A, van Vugt M, Ammatuna E, van Rijn RS, Vellenga E, van den Berg A, Fehrmann RSN, van Meerten T. de Jong MRW, et al. Among authors: huls g. PLoS One. 2018 Feb 28;13(2):e0193098. doi: 10.1371/journal.pone.0193098. eCollection 2018. PLoS One. 2018. PMID: 29489886 Free PMC article.
Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis.
He Y, Bouwstra R, Wiersma VR, de Jong M, Jan Lourens H, Fehrmann R, de Bruyn M, Ammatuna E, Huls G, van Meerten T, Bremer E. He Y, et al. Among authors: huls g. Nat Commun. 2019 Feb 1;10(1):533. doi: 10.1038/s41467-018-08013-z. Nat Commun. 2019. PMID: 30710089 Free PMC article.
Tumour necrosis as assessed with 18F-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements.
Kahle XU, Hovingh M, Noordzij W, Seitz A, Diepstra A, Visser L, van den Berg A, van Meerten T, Huls G, Boellaard R, Kwee TC, Nijland M. Kahle XU, et al. Among authors: huls g. Eur Radiol. 2019 Nov;29(11):6018-6028. doi: 10.1007/s00330-019-06178-9. Epub 2019 Apr 26. Eur Radiol. 2019. PMID: 31028445 Free PMC article.
CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.
Bouwstra R, He Y, de Boer J, Kooistra H, Cendrowicz E, Fehrmann RSN, Ammatuna E, Zu Eulenburg C, Nijland M, Huls G, Bremer E, van Meerten T. Bouwstra R, et al. Among authors: huls g. Cancer Immunol Res. 2019 Oct;7(10):1663-1671. doi: 10.1158/2326-6066.CIR-18-0781. Epub 2019 Aug 13. Cancer Immunol Res. 2019. PMID: 31409608
199 results